Condition
Patients With BRAFV600 E or BRAFV600K Mutation
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Binimetinib
Research Leaders
5 sponsors active, led by Coordinating Centre for Clinical Trials Heidelberg
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Binimetinib1
- Encorafenib1
Active Sponsors
- Coordinating Centre for Clinical Trials Heidelberg1
- Array BioPharma1
- University Hospital Heidelberg1
- University of Heidelberg Medical Center1
- German Cancer Research Center1
Top Investigators
Medizinische Klinik V, University Hospital Heidelberg
Related Conditions
- Relapsed Or Refractory Multiple Myeloma1